Anna Protopapas - Jul 15, 2021 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)

Role
President & CEO, Director
Signature
/s/ Brian DeSchuytner, as Attorney-in-Fact
Stock symbol
MRSN
Transactions as of
Jul 15, 2021
Transactions value $
-$513,186
Form type
4
Date filed
7/19/2021, 08:49 PM
Previous filing
Jun 7, 2021
Next filing
Jan 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRSN Common Stock Options Exercise +100K +44.46% 325K Jul 15, 2021 Direct F1
transaction MRSN Common Stock Sale -$250K -20K -6.17% $12.47 305K Jul 16, 2021 Direct F2, F3
transaction MRSN Common Stock Sale -$263K -21.9K -7.18% $12.02 283K Jul 19, 2021 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRSN Restricted Stock Units Options Exercise $0 -100K -100% $0.00* 0 Jul 15, 2021 Common Stock 100K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") listed in Table II represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F2 Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy her tax withholding obligations and does not represent a discretionary trade by the reporting person
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.27 to $12.61, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.90 to $12.23, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5 The RSUs vested in their entirety on July 15, 2021.